The Oncology Institute, Inc.
$4.23
-7.8%The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -7.8).
Valuation inputs: P/E -7.8, earnings yield N/A, momentum -7.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +3.9%, ROIC -35.7%).
Profitability stack: net margin -12.1%, ROE +3.9%, ROIC -35.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +109.5%, momentum -7.8%, net margin -12.1%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
The Oncology Institute, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
The Oncology Institute, Inc. Fair Value Envelope
The Oncology Institute, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
The Oncology Institute, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
The Oncology Institute, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
The Oncology Institute, Inc. Street Expectations Map
Wall Street analysts project that TOI stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 7.00, with estimates ranging from a low of 5.00 to a high of 10.00.
The consensus 1-year price target stands at 7.00, with estimates ranging from a low of 5.00 to a high of 10.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
The Oncology Institute, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.28M and sold $3.63M worth of TOI shares, resulting in $1.35M of net selling activity.
3 Months
714.9K
2.28M
95.7K
335.13K
+1.9M
+$1.94M
3-6 Months
0
0.00
13.6K
51.17K
-51K
-$51K
6-9 Months
0
0.00
2.2K
8.64K
-9K
-$9K
9-12 Months
0
0.00
1.5M
3.24M
-3.2M
-$3.24M
Top Buyers
Chernett Jorey
10 Percent Owner
$2.28M
Top Sellers
M33 Growth I L.P.
Director, 10 Percent Owner:
$2.34M
Barasch Richard A
Director
$814K
Kaushal Mohit
Director
$335K
Hively Brad
Director
$132K
Pacala Mark L
Director
$9K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $1.35M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
TOI has not reported any dividend yield values in the available annual periods.
toi Dividend History
Learning Layer
Related Guides
Build conviction on TOI by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.